Phase I trial of Exisulind (Aptosyn™) and CPT-11 in patients with colorectal cancer and other solid tumors.

被引：0
|
作者：
Marshall, JL [1 ]
Park, S [1 ]
Al-Sayed, A [1 ]
Fox, E [1 ]
Rizvi, N [1 ]
机构：
[1] Vincent T Lombardi Canc Res Ctr, Washington, DC USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
295
引用
收藏
页码：3713S / 3713S
页数：1
相关论文
共 50 条
  • [41] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [42] Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy
    García-Girón C.
    Palomo A.G.
    López C.A.
    Carbonero A.L.
    Ureña M.M.
    Cebrián E.A.
    Galíndez R.B.
    Yustos M.A.
    Gallego J.A.
    Clinical and Translational Oncology, 2005, 7 (6) : 244 - 249
  • [43] Phase I clinical study of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC).
    Paz-Ares, L
    Garcia-Alfonso, P
    Castellanos, D
    Martin, B
    Perez-Manga, G
    Cortes-Funes, H
    Gonzalez, J
    Gravalos, C
    CLINICAL CANCER RESEARCH, 2000, 6 : 4575S - 4575S
  • [44] Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients.: Preliminary results of a phase I/II trial.
    Losa, F
    Manzano, H
    Vicente, P
    Rifa, J
    Ocaña, J
    Balcells, M
    Mediavilla, D
    Heras, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 288S - 288S
  • [45] Phase I/II trial of gemcitabine (Gem) plus irinotecan (CPT-11) for metastatic pancreatic cancer (MPC)
    Yamai, Takuo
    Ioka, Tatsuya
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [46] Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
    Raymond, E
    Vernillet, L
    Boige, V
    Hua, A
    Ducreux, M
    Mekhaldi, S
    Jacques, C
    Gatineau, M
    Mignard, D
    Vergniol, JC
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S284
  • [47] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [48] Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients
    Slatter, JG
    Schaaf, LJ
    Sams, JP
    Feenstra, KL
    Johnson, MG
    Bombardt, PA
    Cathcart, KS
    Verburg, MT
    Pearson, LK
    Compton, LD
    Miller, LL
    Baker, DS
    Pesheck, CV
    Lord, RS
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (04) : 423 - 433
  • [49] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [50] Pemetrexed in combination with paclitaxel: A phase I clinical and pharmacokinetic trial in patients with solid tumors.
    Graefe, T.
    Bolling, C.
    Lubbing, C.
    Latz, J.
    Blatter, J.
    Hanauske, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
12345